Intrahippocampal Injection Of Lipopolysaccharide Research Articles

Plasmin deficiency leads to fibrin accumulation and a compromised inflammatory response in the mouse brain

Excess fibrin in blood vessels is cleared by plasmin, the key proteolytic enzyme in fibrinolysis. Neurological disorders and head trauma can result in the disruption of the neurovasculature and the entry of fibrin and other blood components into the brain, which may contribute to further neurological dysfunction. While chronic fibrin deposition is often implicated in neurological disorders, the pathological contributions attributable specifically to fibrin have been difficult to ascertain. An animal model that spontaneously acquires fibrin deposits could allow researchers to better understand the impact of fibrin in neurological disorders. Brains of plasminogen (plg)- and tissue plasminogen activator (tPA)-deficient mice were examined and characterized with regard to fibrin accumulation, vascular and neuronal health, and inflammation. Furthermore, the inflammatory response following intrahippocampal lipopolysaccharide (LPS) injection was compared between plg(-/-) and wild type (WT) mice. Both plg(-/-) and tPA(-/-) mice exhibited brain parenchymal fibrin deposits that appear to result from reduced neurovascular integrity. Markers of neuronal health and inflammation were not significantly affected by proximity to the vascular lesions. A compromised neuroinflammatory response was also observed in plg(-/-) compared to WT mice following intrahippocampal LPS injection. These results demonstrate that fibrin does not affect neuronal health in the absence of inflammation and suggest that plasmin may be necessary for a normal neuroinflammatory response in the mouse CNS.

Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: Implication for a new schizophrenia animal model

Several lines of evidence have suggested that the dysregulation of immune system is involved in the pathogenesis of schizophrenia. Microglia are the resident macrophage of the brain and the major player in innate immunity in the brain. We hypothesized that microglia activation may be closely associated with the neuropathology of schizophrenia. Neonatal intrahippocampal injection of lipopolysaccharide (LPS), an activator of microglia, was performed in rats at postnatal day 7 (PD7), and they were separately treated with saline or minocycline for consecutive 3days. Behavioral changes (locomotor activity, social interaction and prepulse inhibition) were examined in adulthood, and the number of microglia was assessed using immunohistochemistry at PD9, PD21 and PD67. The adult rats in LPS-injected group showed obvious behavioral alterations (deficits in social behavior and prepulse inhibition) and a persistently dramatic increase of number of activated microglial cells in the hippocampus, cerebral cortex and thalamus compared to those in saline-injected group. Interestingly, pretreatment with minocycline could significantly rescue the behavioral deficits and prevent microglia activation. Our results suggest that neonatal intrahippocampal LPS injection may serve as a potential schizophrenia animal model, and inhibition of microglia activation may be a potential treatment strategy for schizophrenia.

Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons

An inflammatory reaction in the brain is primarily characterized by activation of parenchymal microglial cells. Microglia regulate several aspects of adult neurogenesis, i.e. the continuous production of new neurons in the adult brain. Hippocampal neurogenesis is thought to be important for memory formation, but its role in brain diseases is not clear. We have previously shown that brain inflammation modulates the functional integration of newly formed hippocampal neurons. Here, we explored whether there is a defined time period during synaptic development when new neurons are susceptible to brain inflammation. Newly formed hippocampal neurons, born in an intact environment in the adult mouse brain, were exposed to lipopolysaccharide (LPS)-induced inflammation during either early or late phases of excitatory and inhibitory synaptogenesis. We used intra-hippocampal injections of GFP-retroviral vector (RV-GFP) to label the new neurons and ipsilateral LPS injection at either 1 or 4weeks post-RV-GFP injection. A single intra-hippocampal LPS injection induced an inflammatory response for at least 3weeks, including an acute transient pro-inflammatory cytokine release as well as a sub-acute and sustained change in microglial morphology. The general cytoarchitecture of the hippocampal dentate gyrus, including granule cell layer (GCL) volume, and astrocytic glial fibrillary acidic protein expression was not different compared to vehicle controls, and no Fluoro-Jade-positive cell death was observed. New neurons encountering this inflammatory environment exhibited no changes in their gross morphology. However, when inflammation occurred during early stages of synapse formation, we found a region-specific increase in the number of thin dendritic spines and post-synaptic density-95 (PSD-95) cluster formation on spines, suggesting an enhanced excitatory synaptic connectivity in the newborn neurons. No changes were observed in the expression of N-cadherin, an adhesion molecule primarily associated with excitatory synapses. At the inhibitory synapses, alterations due to inflammation were also evident during early but not later stages of synaptic development. Gephyrin, an inhibitory scaffolding protein, was down-regulated in the somatic region, while the adhesion molecules neuroligin-2 (NL-2) and neurofascin were increased in the somatic region and/or on the dendrites. The GABAA receptor-α2 subunit (GABAAR-α2) was increased, while pre/peri-synaptic GABA clustering remained unaltered. The disproportional changes in post-synaptic adhesion molecules and GABAA receptor compared to scaffolding protein expression at the inhibitory synapses during brain inflammation are likely to cause an imbalance in GABAergic transmission. These changes were specific for the newborn neurons and were not observed when estimating the overall expression of gephyrin, NL-2, and GABAAR-α2 in the hippocampal GCL. The expression of interleukin-1-type 1 receptor (IL-1R1) on preferentially the somatic region of new neurons, often in close apposition to NL-2 clusters, may indicate a direct interaction between brain inflammation and synaptic proteins on newborn neurons. In summary, this study provides evidence that adult-born hippocampal neurons alter their inhibitory and excitatory synaptic integration when encountering an LPS-induced brain inflammation during the initial stages of synapse formation. Changes at this critical developmental period are likely to interfere with the physiological functions of new neurons within the hippocampus.

Intra-hippocampal injection of lipopolysaccharide inhibits kindled seizures and retards kindling rate in adult rats

Neuroinflammation facilitates seizure acquisition and epileptogenesis in developing brain. Yet, the studies on impact of neuroinflammation on mature brain epileptogenesis have led to inconsistent results. Hippocampus is particularly vulnerable to damage caused by ischemia, hypoxia and trauma, and the consequent neuroinflammation, which can lead in turn to epilepsy. Lipopolysaccharide (LPS) is extensively used in experimental studies to induce neuroinflammation. In this study, effect of acute and chronic intra-CA1 infusion of LPS on amygdala-kindled seizures and epileptogenesis was examined in mature rats. LPS (5μg/rat) inhibited evoked amygdala afterdischarges and behavioral seizures. Anticonvulsant effect of LPS was observed 0.5h after administration and continued up to 24h. This effect was accompanied by intra-hippocampal elevation of nitric oxide (NO), interleukin1-β, and tumor necrosis factor-α and was prevented by microglia inhibitor, naloxone, NO synthase inhibitor, Nω-nitro-L-arginine methyl ester, cyclooxygenase inhibitor, piroxicam, and interleukin1-β receptor antagonist, interleukin1-ra. Moreover, daily intra-hippocampal injection of LPS significantly retarded kindling rate. In order to further elucidate the effect of LPS on synaptic transmission and short-term plasticity, changes in field excitatory postsynaptic potentials and population spikes were measured in stratum radiatum and stratum pyramidale of LPS-treated kindled rats. LPS impaired baseline synaptic transmission in hippocampal Schaffer collateral-CA1 synapse and reduced the magnitude of paired-pulse facilitation. Our results suggest that direct suppression of presynaptic mechanisms in Schaffer collateral-CA1 synapses, as well as the inflammatory mediators released by LPS in the hippocampus, is involved in antiepileptic effect of LPS.

Lipopolysaccharide induces paired immunoglobulin-like receptor B (PirB) expression, synaptic alteration, and learning–memory deficit in rats

Some typical immune proteins are expressed in the nervous system, among which the paired-immunoglobulin-like receptor B (PirB) is a receptor for major histocompatibility complex class I antigen (MHC-I), but may play a physiological role in the brain for neuronal circuitry stability by inhibiting synaptic plasticity. Chronic neuroinflammation is common to many neurodegenerative diseases and is often associated with neuronal/synaptic damage and dysfunction. Here we examined the expression of PirB in the rat brain following intracerebral application of lipopolysaccharide (LPS), which has been shown to induce proinflammatory changes and cognitive deficits in rodents. One month after unilateral intrahippocampal LPS injection (10 μg in 4 μl phosphate-buffered saline, PBS), increased protein levels and immunoreactivity of PirB were detected in the ipsilateral hippocampal formation and cortex of the experimental group relative to vehicle (PBS) control. The increased PirB labeling was localized to astrocytes and neurons. Reduced synaptophysin protein levels and immunoreactivity were also found in the ipsilateral hippocampal formation and cortex in LPS-treated rats relative to controls. Morris water maze tests indicated that hippocampus-dependent spatial learning and memory were impaired in LPS-treated animals. Our findings add new experimental data for an upregulation of immune proteins in neuronal and glial cells in the brain in a model of endotoxin-induced neuroinflammation, synaptic alteration, and cognitive decline. The results suggest that PirB modulation may be involved in the pathological process under neurodegenerative conditions.

In vivo bioluminescence imaging of bone marrow-derived cells in brain inflammation

It has been accepted that bone marrow cells infiltrate the brain and play important roles in neuroinflammation. However, there is no good tool for the visualization of these cells in living animals. In this study, we generated mice that were transplanted with GFP- or luciferase-expressing bone marrow cells, and performed in vivo fluorescence imaging (FLI) and in vivo bioluminescence imaging (BLI) to visualize the infiltrated cells. Brain inflammation was induced by intrahippocampal injection of lipopolysaccharide (LPS). Immunohistochemical investigation demonstrated an increase in the infiltration of bone marrow cells into the hippocampus because of the LPS injection and differentiation of the infiltrated cells into microglia, but not into neurons or astrocytes. BLI, but not FLI, successfully detected an increase in signal intensity with the LPS injection, and the increase of BLI coincided with that of luciferase activity in hippocampus. BLI could quantitatively and continuously monitor bone marrow-derived cells in vivo.

Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes

Previous investigations have showed that triptolide possessed potent anti-inflammatory and immunosuppressive properties. In the present study, we examined the protective effects of triptolide on the inflammatory response induced by bacterial lipopolysaccharide (LPS) both in vivo and in vitro. Intrahippocampal injection of LPS (4 μg) in rats significantly increased the immunoreactivity of glial fibrillary acid protein (GFAP) and cyclooxygenase-2 (COX-2) in the injected region, which was reduced by pretreatment with triptolide (10–50 μg/kg) for 5 d. In the cultured human differentiated A172 astroglial cells, LPS (1 mg/L) increased the expression of COX-2 mRNA and protein, the production of prostaglandin E 2 (PGE 2) and the DNA binding activity of NF-kappa B, which were markedly attenuated by pretreatment with triptolide (0.2–5 μg/L) for 1 h. These results suggested that the protective effect of triptolide on neuroinflammation is mediated by decreasing COX-2 expression, at least partly, via the inhibition of NF-kappa B signaling pathway.

Diverse microglial responses after intrahippocampal administration of lipopolysaccharide

Inflammation has been argued to play a primary role in the pathogenesis of Alzheimer's disease by contributing to the development of neuropathology and clinical symptoms. However, the mechanisms underlying these effects remain obscure. Lipopolysaccharide (LPS) activates the innate immune response and triggers gliosis when injected into the central nervous system. In the studies described in the present work, we evaluated the time course of microgliosis after a single intrahippocampal injection of LPS. Mice were injected bilaterally with 4 mug of LPS. Post-injection survival times were 1, 6, and 24 h, as well as 3, 7, 14, and 28 days. Protein and RNA analyses were performed for inflammatory markers. Significant elevations of cluster differentiation marker CD45, glial fibrillary acidic protein (GFAP), scavenger receptor A (SRA), and Fcgamma receptor mRNA were seen after 24 h. Immunohistochemistry revealed a complex pattern of protein expression by microglia, as well as changes in cell morphologies. RNA and protein for Fcgamma receptor and SRA were transiently elevated, peaked at 3 days, and returned to basal levels after 1 week. In contrast, microglia remained significantly activated through the 28-day time point, as determined by CD45 and complement receptor 3 levels. These findings indicate a multivariate response to LPS, and evaluation of microglial phenotypes may lead to a better understanding of neuroinflammatory diseases.

Differential injury-dependent glial expression of interleukins-1?, ?, and interleukin-6 in rat brain

Interleukins (IL)-1 alpha, beta and IL-6 may play essential roles in early inflammatory processes in response to degenerating cholinergic cells observed in the basal forebrain of Alzheimer patients. To address this question in vivo, two distinct lesion paradigms were used. A specific and selective basal forebrain cholinergic cell loss was achieved by a single intracerebroventricular application of the cholinergic immunotoxin, 192IgG-saporin. Intrahippocampal injection of lipopolysaccharide and interferon-gamma was used to produce an exogenously-induced acute inflammation in the brain. In order to disclose the lesion-induced temporal cascade of the expression pattern of IL-1 alpha, IL-1 beta, and IL-6, and the cell types expressing IL-1 alpha, beta/IL-6 mRNA, Western analysis, RT-PCR, and double labeling immunocytochemistry were applied. In the intact brain, IL-6, IL-1 alpha and IL-1 beta demonstrated a constitutive expression in neurons. Following cholinergic lesion neither IL-1 beta nor IL-6 expression could be detected in any of the activated glial cell types, whereas IL-1 alpha was found to be expressed in astroglial cells only. In contrast, hippocampal administration of lipopolysaccharides/interferon-gamma resulted in expression of IL-1 alpha in microglial but not astroglial cells. These in vivo studies clearly demonstrate that the cellular expression of IL-1 alpha, IL-1 beta, and IL-6 in the brain is differentially regulated depending on the kind of injury producing the inflammatory response in the brain. The data suggest that each glial cell seems to be equally capable of expressing a number of various cytokines, but it depends on the kind of stimulus which temporal and cellular cascade of cytokine expression pattern is initiated under a particular pathological condition in the brain.

Differential injury‐dependent glial expression of interleukins‐1α, β, and interleukin‐6 in rat brain

Interleukins (IL)-1α, β and IL-6 may play essential roles in early inflammatory processes in response to degenerating cholinergic cells observed in the basal forebrain of Alzheimer patients. To address this question in vivo, two distinct lesion paradigms were used. A specific and selective basal forebrain cholinergic cell loss was achieved by a single intracerebroventricular application of the cholinergic immunotoxin, 192IgG-saporin. Intrahippocampal injection of lipopolysaccharide and interferon-γ was used to produce an exogenously-induced acute inflammation in the brain. In order to disclose the lesion-induced temporal cascade of the expression pattern of IL-1α, IL-1β, and IL-6, and the cell types expressing IL-1α, β/IL-6 mRNA, Western analysis, RT-PCR, and double labeling immunocytochemistry were applied. In the intact brain, IL-6, IL-1α and IL-1β demonstrated a constitutive expression in neurons. Following cholinergic lesion neither IL-1β nor IL-6 expression could be detected in any of the activated glial cell types, whereas IL-1α was found to be expressed in astroglial cells only. In contrast, hippocampal administration of lipopolysaccharides/interferon-γ resulted in expression of IL-1α in microglial but not astroglial cells. These in vivo studies clearly demonstrate that the cellular expression of IL-1α, IL-1β, and IL-6 in the brain is differentially regulated depending on the kind of injury producing the inflammatory response in the brain. The data suggest that each glial cell seems to be equally capable of expressing a number of various cytokines, but it depends on the kind of stimulus which temporal and cellular cascade of cytokine expression pattern is initiated under a particular pathological condition in the brain. GLIA 27:75–87, 1999. © 1999 Wiley-Liss, Inc.

Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25-dihydroxyvitamin D3

This study, based on in situ hybridization and immunolabeling experiments, presents the time-course and cellular distribution of inducible NO synthase (iNOS) expression in a rat model of brain inflammation. Both intrahippocampal injection of lipopolysaccharide (LPS) or of buffer (stab lesion) induce an early, transient, and restricted expression of iNOS mRNA and immunoreactivity in the rat CNS. The topographic and phenotypic characteristics of iNOS-producing cells are distinct. After stab lesion, iNOS mRNAs, expressed at 5 h mainly in cells in the interventricular junction and in a few cells in brain parenchyma, were no more detectable from 15 h onwards, whereas the protein was faintly expressed in parenchymal cells at 15 h and 24 h. In contrast, after LPS injection, iNOS-mRNAs were detected from 5 to 24 h. iNOS-immunoreactivity was highly induced and sequentially observed first in choroid plexus and ependymal cells at 5 h, in monocytes and activated/reactive microglia at 15 h and 24 h, and finally in astrocytes at 72 h. In order to investigate potential regulatory effects of 1,25-dihydroxyvitamin D3 (1,25-D3) on iNOS expression, we have delivered this hormone with LPS or buffer into the rat hippocampus. 1,25-D3 significantly inhibits iNOS expression, at both the mRNA and immunoreactive protein levels, 15 h and 24 h after LPS injection, in the cells of the monocyte lineage. Moreover, 72 h after LPS injection, the addition of 1,25-D3 leads to a 6-fold increase in the number of macrophages around the lesion site, that correlates with a decrease in the proportion of apoptotic cells. Since 1,25-D3 can be produced by activated macrophages/microglia and since NO stimulates 1,25-D3 synthesis by macrophages, our results support the hypothesis that this hormone might be synthesized endogenously during CNS inflammatory reactions, thus explaining the transient and restricted iNOS expression observed after LPS intracerebral injection.

Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25‐dihydroxyvitamin D3

This study, based on in situ hybridization and immunolabeling experiments, presents the time-course and cellular distribution of inducible NO synthase (iNOS) expression in a rat model of brain inflammation. Both intrahippocampal injection of lipopolysaccharide (LPS) or of buffer (stab lesion) induce an early, transient, and restricted expression of iNOS mRNA and immunoreactivity in the rat CNS. The topographic and phenotypic characteristics of iNOS-producing cells are distinct. After stab lesion, iNOS mRNAs, expressed at 5 h mainly in cells in the interventricular junction and in a few cells in brain parenchyma, were no more detectable from 15 h onwards, whereas the protein was faintly expressed in parenchymal cells at 15 h and 24 h. In contrast, after LPS injection, iNOS-mRNAs were detected from 5 to 24 h. iNOS-immunoreactivity was highly induced and sequentially observed first in choroid plexus and ependymal cells at 5 h, in monocytes and activated/reactive microglia at 15 h and 24 h, and finally in astrocytes at 72 h. In order to investigate potential regulatory effects of 1,25-dihydroxyvitamin D3 (1,25-D3) on iNOS expression, we have delivered this hormone with LPS or buffer into the rat hippocampus. 1,25-D3 significantly inhibits iNOS expression, at both the mRNA and immunoreactive protein levels, 15 h and 24 h after LPS injection, in the cells of the monocyte lineage. Moreover, 72 h after LPS injection, the addition of 1,25-D3 leads to a 6-fold increase in the number of macrophages around the lesion site, that correlates with a decrease in the proportion of apoptotic cells. Since 1,25-D3 can be produced by activated macrophages/microglia and since NO stimulates 1,25-D3 synthesis by macrophages, our results support the hypothesis that this hormone might be synthesized endogenously during CNS inflammatory reactions, thus explaining the transient and restricted iNOS expression observed after LPS intracerebral injection. GLIA 22:282–294, 1998. © 1998 Wiley-Liss, Inc.